MedTrace Logo

Plasma Biomarker in Amblyopia Patients

NCT05705778 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-01-31

No results posted yet for this study

Summary

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Conditions

  • Amblyopia

Interventions

PROCEDURE

standard amblyopia treatment

amblyopia treatment following international guidelines and genetic tests.

Sponsors & Collaborators

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2025-10-31
Completion
2027-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05705778 on ClinicalTrials.gov